Posted by Michael Wonder on 02 Jul 2026
Galderma provides progress update regarding relabotulinumtoxinA regulatory submission in the US
1 July 2026 - Galderma today provided progress updates regarding the regulatory review of its pending biologics license application for relabotulinumtoxinA with the US FDA.
The Company has received a complete response letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization.
